Leerink Partnrs Estimates enGene FY2030 Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Research analysts at Leerink Partnrs issued their FY2030 earnings estimates for shares of enGene in a research report issued on Tuesday, November 11th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn $1.42 per share for the year. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06).

Other equities research analysts have also recently issued research reports about the stock. Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price for the company in a research report on Tuesday. Oppenheimer reaffirmed an “outperform” rating and set a $33.00 target price (up from $30.00) on shares of enGene in a report on Wednesday. UBS Group boosted their price target on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research note on Wednesday. Citizens Jmp raised their price objective on enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of enGene in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.38.

enGene Stock Performance

NASDAQ ENGN traded down $0.15 on Thursday, reaching $8.54. The stock had a trading volume of 1,591,035 shares, compared to its average volume of 393,891. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The company has a market cap of $436.91 million, a P/E ratio of -4.52 and a beta of -0.27. The firm has a fifty day moving average of $7.20 and a two-hundred day moving average of $4.95. enGene has a 1-year low of $2.65 and a 1-year high of $11.14.

Institutional Trading of enGene

Several hedge funds have recently modified their holdings of ENGN. Cresset Asset Management LLC bought a new position in shares of enGene during the 2nd quarter worth about $36,000. Paloma Partners Management Co acquired a new stake in enGene in the second quarter valued at approximately $38,000. PFS Partners LLC bought a new stake in shares of enGene during the third quarter valued at approximately $61,000. ADAR1 Capital Management LLC bought a new position in shares of enGene in the 1st quarter worth $107,000. Finally, Affinity Asset Advisors LLC acquired a new stake in enGene in the 2nd quarter valued at $280,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.